An observational study in Autism Spectrum Disorder (ASD) and Obstructive Sleep Apnea (OSA), sponsored by Lena Xiao. Recruiting at 1 site in Canada. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Lena Xiao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Autism Spectrum Disorder with a site in Canada — 15 open to participants now, 18 under way, 1 of them phase 3. Autism Spectrum Disorder · Canada.
Among the 70 studies in Autism Spectrum Disorder with a site in Canada, this one is one of 4 that started in 2025, is one of 7 observational ones, reaches primary completion later than 6 of the 17 other live ones, and was the 67th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →15 of the 70 studies in Autism Spectrum Disorder with a site in Canada are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Canada, United States, Australia and 1 more country
Ages 5–17
Western University, Canada · Sites in Canada
Ages up to 47 mo
Holland Bloorview Kids Rehabilitation Hospital · Sites in Canada
Ages 8–17
The Hospital for Sick Children · Sites in Canada
Ages 5–17
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–40 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 60 across the 63 interventional studies, 200 across the 7 observational. Of the 47 that completed or were terminated, 11 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 70 have an industry lead sponsor. The 10 most frequent:
Lena Xiao is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lena Xiao has 1 study filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
8 of the studies in Autism Spectrum Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07245160London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sA Cognitive Behavioral Therapy Approach to Addressing Anxiety in Children With ASD and Intellectual Disability | 2026-12-31 |
| NCT06529380The Hospital for Sick ChildrenDeep Brain Stimulation for Severe Self-Injurious Behaviour in Children | 2026-12-31 |
| NCT07367022Lena XiaoPortable Sleep Monitors in Children With Autism Spectrum Disorder | 2026-12-31 |
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT05916339Daniel CouryAWARE: Management of ADHD in Autism Spectrum Disorder | 2027-01-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 70 studies in Autism Spectrum Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the ability of a portable sleep monitor to detect obstructive sleep apnea in children with autism spectrum disorder (ASD). The main study objectives are to:
Sleep disorders are highly prevalent in children with ASD, with as many as 80% of children reporting poor sleep. To identify the cause of poor sleep, many children will require a sleep study (polysomnogram; PSG), which is an overnight study done at the hospital using many different sensors to measure sleep and breathing. The PSG is the gold standard diagnostic test for obstructive sleep apnea (OSA) and measures the rate of obstructive respiratory events during sleep (obstructive apnea-hypopnea index; OAHI) which is crucial for treatment decision-making. However, PSGs are challenging for children with ASD due to the disrupted routine, burden and stress, and intolerance to the PSG setup. Further, diagnosis may be delayed up to 2 years due to a lack of pediatric sleep facilities in Canada, with pronounced geographical disparities. Although sleep disturbances are prevalent amongst children with ASD, there are significant inequities in accessing pediatric sleep medicine care and diagnostic testing. Alternative, simpler diagnostic testing is needed.
We will evaluate a portable sleep monitor as the first step towards establishing home sleep apnea testing in children with ASD. We will conduct a feasibility study testing the Nox T3s portable sleep monitor alongside the traditional in-hospital polysomnogram to compare the ability of the Nox T3s to identify obstructive sleep apnea in children with ASD. We will also conduct qualitative interviews with families to gather insight on participant and family preferences for sleep testing to better address the needs of children with ASD.
Children who are undergoing a clinical PSG at British Columbia's Children's Hospital in Vancouver, Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children aged 6-18 years old with autism spectrum disorder concurrently testing a portable sleep monitor (Nox T3s) during their first clinical polysomnogram. Children and their caregivers may also complete a qualitative interview about sleep testing preferences after their sleep test.
Device: Portable sleep monitor (Nox T3s)
Participants will test the Nox T3s portable sleep monitor concurrently during their in-hospital clinical polysomnogram.
Obstructive Apnea-Hypopnea Index (OAHI) measured from the portable sleep monitor and from the polysomnogram (PSG)
The OAHI measured from the portable sleep monitor will be compared to the OAHI measured from the PSG, the gold standard test for sleep-disordered breathing, to determine the ability of the portable sleep monitor to diagnose obstructive sleep apnea.
Time frame: Baseline
Patient and Family Preferences
Optional semi-structured qualitative interviews with caregivers and the patient, if they choose to and are capable of participating in the interviews. The interviews will be conducted virtually by a study team member to explore patient and family preferences and experiences with diagnostic sleep testing.
Time frame: 0-3 months after the baseline PSG
Insomnia Questionnaire
The caregiver-reported Pediatric Insomnia Severity Index will be used to measure the severity of pediatric insomnia symptoms. Scores range from 0 to 30, with higher scores indicating greater insomnia severity.
Time frame: +/- 1 week from baseline PSG sleep test
Chronotype Questionnaire
The caregiver-reported Children's Chronotype Questionnaire will measure the chronotype of the participant. The caregiver is given a short description of different chronotypes and selects the chronotype that best reflects their child's preference from a 5-point scale, ranging from "Definitely a Morning Type" = 1 to "Definitely an Evening Type" = 5.
Time frame: +/- 1 week from baseline PSG sleep test
Chronotype Questionnaire
The Morningness/Eveningness Scale from the caregiver-reported Children's Chronotype Questionnaire will measure the participant's differences in activeness and alertness in the mornings and evenings. Scores range from 10-48, with scores indicating a morning type (≤ 23), intermediate type (24-32), and evening type (≥33).
Time frame: +/- 1 week from baseline PSG sleep test
Chronotype Questionnaire
The sleep and wake parameters from the caregiver-reported Children's Chronotype Questionnaire will measure the participant's midsleep point on free days (MSF).
Time frame: +/- 1 week from baseline PSG sleep test
Sleep Questionnaire
The caregiver-reported Pediatric Sleep Questionnaire: Sleep-Related Breathing Disorders subscale will measure the risk for sleep-related breathing disorders. The questionnaire contains 22-items scored as "yes" = 1 and "no" = 0 and normalized to the total number of questions answered, yielding a score between 0.0-1.0. Scores \>0.33 indicate a high risk for sleep-related breathing disorders.
Time frame: +/- 1 week from baseline PSG sleep test
Psychological Scale (Emotional Symptoms)
The Emotional Symptoms subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater emotional difficulties.
Time frame: +/- 1 week from baseline PSG sleep test
Psychological Scale (Conduct Problems)
The Conduct Problems subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater conduct difficulties.
Time frame: +/- 1 week from baseline PSG sleep test
Psychological Scale (Hyperactivity/inattention)
The Hyperactivity/inattention subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater hyperactivity/inattention problems.
Time frame: +/- 1 week from baseline PSG sleep test
Psychological Scale (Peer Relationship Problems)
The Peer Relationship Problems subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater peer relationship problems.
Time frame: +/- 1 week from baseline PSG sleep test
Psychological Scale (Pro-Social)
The Pro-Social subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating less difficulty and an increased aptitude for kind and helpful behaviour.
Time frame: +/- 1 week from baseline PSG sleep test
Psychological Scale (Total Difficulties)
The Total Difficulties/Overall Stress scale of the Strengths and Difficulties Questionnaire will be calculated by totaling the following 4 subscales: emotional, conduct, hyperactivity, and peer relationships. The total score ranges from 0-40, with greater scores indicating greater difficulties and overall stress.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Auditory Hypersensitivity)
The Auditory Hypersensitivity subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 9-36, with greater scores indicating higher sensitivity for, and problems with, sounds related to auditory danger signals.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Auditory Hyposensitivity to Voices)
The Auditory Hyposensitivity to Voices subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 5-20, with greater scores indicating reduced sensitivity for speech or voices.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Visual Hypersensitivity)
The Visual Hypersensitivity subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 10-40, with greater scores indicating increased sensitivity to light and movement.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Tactile Hypersensitivity)
The Tactile Hypersensitivity subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 10-40, with greater scores indicating increased sensitivity to non-social touch.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Affiliative Touch Aversion)
The Affiliative Touch Aversion subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 3-12, with greater scores indicating increased negative response to social touch.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Selective Eating)
The Selective Eating subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 6-24, with greater scores indicating increased selectivity in food choices (i.e. picky eating).
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Ingestive Problems)
The Ingestive Problems subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 3-12, with greater scores indicating increased problems with swallowing and retaining food.
Time frame: +/- 1 week from baseline PSG sleep test
Sensory Scale (Digestive Problems)
The Digestive Problems subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 4-16, with greater scores indicating increased problems with digestion.
Time frame: +/- 1 week from baseline PSG sleep test
Autism Symptoms Dimensions Scale
The caregiver-reported Autism Symptoms Dimensions Scale (ASDS) will be used to measure core autism symptoms in children and adolescents. The 39-item questionnaire is scored on a 5-point scale with total ASDS scores ranging from 39-195. Scores between 114-130 indicate high symptom levels and scores \>130 indicate very high symptom levels.
Time frame: +/- 1 week from baseline PSG sleep test
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 16 months is below that.
Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lena Xiao